At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Placebo-controlled, Single-blind Trial To Assess The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine When Administered In Either 2- Or 3-dose Regimens In Healthy Subjects Aged Greater Than Or Equal To 11 To <19 Years
In Brief
A Phase 2 clinical trial evaluating Vaccine for Meningococcal Vaccine. Completed, enrolled 1,714 participants across 63 sites in 7 countries.
Detailed Summary
This study is to look at a new vaccine that might prevent meningococcal disease, and to look at the safety of the new vaccine as well as how well it is tolerated. This study will also look at this vaccine being given 2 or 3 times. This study will be done in healthy adolescents.
Study Details
Timeline
Interventions
rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
rLP2086 at visits 1 and 3, saline at visits 2 and 5
rLP2086 at visits 3 and 5, saline at visits 1 and 2